The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology
AffiliationSource Health Economics, Oxford, UK email@example.com.
MetadataShow full item record
AbstractBackground: Clinical guidelines recommend that parenteral nutrition (PN) is added to enteral nutrition (EN; supplemental parenteral nutrition (SPN)) in order to meet energy and protein needs in patients with cancer when EN alone is insufficient. However, although cancer-related malnutrition is common, there is poor awareness of the value of nutritional care, resulting in SPN being chronically underused. Methods: We performed a targeted literature review and exploratory cost-utility analysis to gather evidence on the clinical effectiveness of SPN, and to estimate the potential cost-effectiveness of SPN versus EN alone in an example cancer setting. Results: The literature review identified studies linking SPN with malnutrition markers, and studies linking malnutrition markers with clinical outcomes. SPN was linked to improvements in body mass index (BMI), fat-free mass, phase angle (PhA) and prealbumin. Of these markers, BMI and PhA were strong predictors of survival. By combining published data, we generated indirect estimates of the overall survival HR associated with SPN; these ranged from 0.80 to 0.99 (mode 0.87). In patients with Stage IV inoperable pancreatic cancer, the incremental cost-effectiveness ratio versus EN alone was estimated to be £41 350 or £91 501 depending on whether nursing and home delivery costs for EN and SPN were combined or provided separately. Conclusion: Despite a lack of direct evidence, the results of the literature review demonstrate that SPN may provide important clinical and quality of life benefits to patients with cancer. The potential for any improvement in outcomes in the modelled patient population is very limited, so cost-effectiveness may be greater in patients with less severe disease and other types of cancer. Keywords: cancer; cost-effectiveness; malnutrition; supplemental parenteral nutrition; targeted literature review.
CitationWebb N, Fricke J, Hancock E, Trueman D, Ghosh S, Winstone J, et al. The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology. ESMO Open. 2020;5(3).
- A randomized trial of supplemental parenteral nutrition in underweight and overweight critically ill patients: the TOP-UP pilot trial.
- Authors: Wischmeyer PE, Hasselmann M, Kummerlen C, Kozar R, Kutsogiannis DJ, Karvellas CJ, Besecker B, Evans DK, Preiser JC, Gramlich L, Jeejeebhoy K, Dhaliwal R, Jiang X, Day AG, Heyland DK
- Issue date: 2017 Jun 9
- Supplemental parenteral nutrition in intensive care patients: A cost saving strategy.
- Authors: Pradelli L, Graf S, Pichard C, Berger MM
- Issue date: 2018 Apr
- Economic burden of hospital malnutrition and the cost-benefit of supplemental parenteral nutrition in critically ill patients in Latin America.
- Authors: Correia MITD, Perman MI, Pradelli L, Omaralsaleh AJ, Waitzberg DL
- Issue date: 2018 Nov
- Early enteral and parenteral nutrition on immune functions of neurocritically ill patients.
- Authors: Qi SY, Wang WT, Chen CY, Chu ZD, Liu XJ, Liu XJ
- Issue date: 2016 Jan-Mar
- Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk.
- Authors: Caccialanza R, Cereda E, Caraccia M, Klersy C, Nardi M, Cappello S, Borioli V, Turri A, Imarisio I, Lasagna A, Saddi J, Arcaini L, Benazzo M, Stragliotto S, Zagonel V, Pedrazzoli P
- Issue date: 2019 Jul